Year |
Citation |
Score |
2023 |
Hosen N. [Identifying and targeting multiple myeloma-specific antigens resulting from post-translational protein modifications by CAR-T cell therapies]. [Rinsho Ketsueki] the Japanese Journal of Clinical Hematology. 64: 427-431. PMID 37271535 DOI: 10.11406/rinketsu.64.427 |
0.348 |
|
2023 |
Naito Y, Koyama S, Masuhiro K, Hirai T, Uenami T, Inoue T, Osa A, Machiyama H, Watanabe G, Sax N, Villa J, Kinugasa-Katayama Y, Nojima S, Yaga M, Hosono Y, ... ... Hosen N, et al. Tumor-derived semaphorin 4A improves PD-1-blocking antibody efficacy by enhancing CD8 T cell cytotoxicity and proliferation. Science Advances. 9: eade0718. PMID 37205755 DOI: 10.1126/sciadv.ade0718 |
0.321 |
|
2023 |
Inui H, Nishida M, Ichii M, Nakaoka H, Asaji M, Ide S, Saito S, Saga A, Omatsu T, Tanaka K, Kanno K, Chang J, Zhu Y, Okada T, Okuzaki D, ... ... Hosen N, et al. XCR1 conventional dendritic cell-induced CD4 T helper 1 cell activation exacerbates cardiac remodeling after ischemic myocardial injury. Journal of Molecular and Cellular Cardiology. 176: 68-83. PMID 36739942 DOI: 10.1016/j.yjmcc.2023.01.011 |
0.33 |
|
2022 |
Nakagawa T, Kijima N, Hasegawa K, Ikeda S, Yaga M, Wibowo T, Tachi T, Kuroda H, Hirayama R, Okita Y, Kinoshita M, Kagawa N, Kanemura Y, Hosen N, Kishima H. Identification of glioblastoma-specific antigens expressed in patient-derived tumor cells as candidate targets for chimeric antigen receptor T cell therapy. Neuro-Oncology Advances. 5: vdac177. PMID 36601313 DOI: 10.1093/noajnl/vdac177 |
0.326 |
|
2022 |
Fujiki F, Morimoto S, Katsuhara A, Okuda A, Ogawa S, Ueda E, Miyazaki M, Isotani A, Ikawa M, Nishida S, Nakajima H, Tsuboi A, Oka Y, Nakata J, Hosen N, et al. T Cell-Intrinsic Vitamin A Metabolism and Its Signaling Are Targets for Memory T Cell-Based Cancer Immunotherapy. Frontiers in Immunology. 13: 935465. PMID 35844620 DOI: 10.3389/fimmu.2022.935465 |
0.415 |
|
2022 |
Yoshinaga Y, Soma T, Azuma S, Maruyama K, Hashikawa Y, Katayama T, Sasamoto Y, Takayanagi H, Hosen N, Shiina T, Ogasawara K, Hayashi R, Nishida K. Long-term survival in non-human primates of stem cell-derived, MHC-unmatched corneal epithelial cell sheets. Stem Cell Reports. 17: 1714-1729. PMID 35750044 DOI: 10.1016/j.stemcr.2022.05.018 |
0.393 |
|
2022 |
Ozawa T, Fujii K, Sudo T, Doi Y, Nakai R, Shingai Y, Ueda T, Baba Y, Hosen N, Yokota T. Special AT-Rich Sequence-Binding Protein 1 Supports Survival and Maturation of Naive B Cells Stimulated by B Cell Receptors. Journal of Immunology (Baltimore, Md. : 1950). 208: 1937-1946. PMID 35379742 DOI: 10.4049/jimmunol.2101097 |
0.573 |
|
2022 |
Higa T, Okita Y, Matsumoto A, Nakayama S, Oka T, Sugahara O, Koga D, Takeishi S, Nakatsumi H, Hosen N, Robine S, Taketo MM, Sato T, Nakayama KI. Spatiotemporal reprogramming of differentiated cells underlies regeneration and neoplasia in the intestinal epithelium. Nature Communications. 13: 1500. PMID 35314700 DOI: 10.1038/s41467-022-29165-z |
0.393 |
|
2022 |
Hamanaka Y, Tanimura A, Yokota T, Ezoe S, Ichii M, Nagate Y, Oritani K, Kanakura Y, Hosen N, Shibayama H. Impaired B cell terminal differentiation in B cell-specific knockout mice of cell death-defying factor anamorsin. Biochemical and Biophysical Research Communications. 603: 1-6. PMID 35259639 DOI: 10.1016/j.bbrc.2022.03.018 |
0.5 |
|
2022 |
Hasegawa K, Ikeda S, Yaga M, Watanabe K, Urakawa R, Iehara A, Iwai M, Hashiguchi S, Morimoto S, Fujiki F, Nakajima H, Nakata J, Nishida S, Tsuboi A, Oka Y, ... ... Hosen N, et al. Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain. Science Translational Medicine. 14: eaax7706. PMID 35171652 DOI: 10.1126/scitranslmed.aax7706 |
0.33 |
|
2021 |
Nakajima H, Nakata J, Imafuku K, Hayashibara H, Isokawa K, Udaka K, Fujiki F, Morimoto S, Hasegawa K, Hosen N, Hashii Y, Nishida S, Tsuboi A, Oka Y, Oji Y, et al. Identification of mouse helper epitopes for WT1-specific CD4 T cells. Cancer Immunology, Immunotherapy : Cii. PMID 34272593 DOI: 10.1007/s00262-021-03003-5 |
0.339 |
|
2021 |
Hosen N. [Chimeric antigen receptor T-cell therapy for multiple myeloma]. [Rinsho Ketsueki] the Japanese Journal of Clinical Hematology. 62: 619-623. PMID 34219089 DOI: 10.11406/rinketsu.62.619 |
0.398 |
|
2021 |
Hosen N, Yoshihara S, Takamatsu H, Ri M, Nagata Y, Kosugi H, Shimomura Y, Hanamura I, Fuji S, Minauchi K, Kuroda J, Suzuki R, Nishimura N, Uoshima N, Nakamae H, et al. Expression of activated integrin β7 in multiple myeloma patients. International Journal of Hematology. 114: 3-7. PMID 33999338 DOI: 10.1007/s12185-021-03162-2 |
0.312 |
|
2021 |
Shingai Y, Yokota T, Okuzaki D, Sudo T, Ishibashi T, Doi Y, Ueda T, Ozawa T, Nakai R, Tanimura A, Ichii M, Shibayama H, Kanakura Y, Hosen N. Autonomous TGFβ signaling induces phenotypic variation in human acute myeloid leukemia. Stem Cells (Dayton, Ohio). PMID 33539590 DOI: 10.1002/stem.3348 |
0.434 |
|
2020 |
Saito H, Ichii M, Toda J, Kitai Y, Muromoto R, Kashiwakura JI, Saitoh K, Tanimura A, Yokota T, Shibayama H, Matsuda T, Oritani K, Kanakura Y, Hosen N. Graft-versus-host disease develops in mice transplanted with lymphocyte-depleted bone marrow cells from signal-transducing adaptor protein-2 transgenic mice. Biochemical and Biophysical Research Communications. 537: 118-124. PMID 33388414 DOI: 10.1016/j.bbrc.2020.12.080 |
0.307 |
|
2020 |
Ichii M, Hosen N. Current Understanding of Myelomatous Mesenchymal Stromal Cells Extended through Advances in Experimental Methods. Cancers. 13. PMID 33374627 DOI: 10.3390/cancers13010025 |
0.379 |
|
2020 |
Hosen N. CAR T cell therapy. Immunological Medicine. 1-5. PMID 32693699 DOI: 10.1080/25785826.2020.1796063 |
0.36 |
|
2020 |
Hosen N. Integrins in multiple myeloma. Inflammation and Regeneration. 40: 4. PMID 32256871 DOI: 10.1186/s41232-020-00113-y |
0.304 |
|
2020 |
Hosen N. Chimeric antigen receptor T-cell therapy for multiple myeloma. International Journal of Hematology. PMID 31981097 DOI: 10.1007/s12185-020-02827-8 |
0.37 |
|
2019 |
Hosen N. Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma. Cancers. 11. PMID 31847470 DOI: 10.3390/cancers11122024 |
0.375 |
|
2019 |
Hasegawa K, Hosen N. Chimeric antigen receptor T cell therapy for multiple myeloma. Inflammation and Regeneration. 39: 10. PMID 31171941 DOI: 10.1186/s41232-019-0100-6 |
0.453 |
|
2018 |
Morimoto S, Fujiki F, Kondo K, Nakajima H, Kobayashi Y, Inatome M, Aoyama N, Nishida Y, Tsuboi A, Oka Y, Nishida S, Nakata J, Hosen N, Oji Y, Sugiyama H. Establishment of a novel platform cell line for efficient and precise evaluation of T cell receptor functional avidity. Oncotarget. 9: 34132-34141. PMID 30344927 DOI: 10.18632/oncotarget.26139 |
0.371 |
|
2018 |
Hosen N. [Chimeric antigen receptor T-cell therapy for multiple myeloma]. [Rinsho Ketsueki] the Japanese Journal of Clinical Hematology. 59: 2189-2194. PMID 30305525 DOI: 10.11406/rinketsu.59.2189 |
0.452 |
|
2017 |
Hosen N, Matsunaga Y, Hasegawa K, Matsuno H, Nakamura Y, Makita M, Watanabe K, Yoshida M, Satoh K, Morimoto S, Fujiki F, Nakajima H, Nakata J, Nishida S, Tsuboi A, et al. The activated conformation of integrin β7 is a novel multiple myeloma-specific target for CAR T cell therapy. Nature Medicine. PMID 29106400 DOI: 10.1038/nm.4431 |
0.301 |
|
2016 |
Hasegawa K, Tanaka S, Fujiki F, Morimoto S, Nakano K, Kinoshita H, Okumura A, Fujioka Y, Urakawa R, Nakajima H, Tatsumi N, Nakata J, Takashima S, Nishida S, Tsuboi A, ... ... Hosen N, et al. Glycosylation Status of CD43 Protein Is Associated with Resistance of Leukemia Cells to CTL-Mediated Cytolysis. Plos One. 11: e0152326. PMID 27011118 DOI: 10.1371/journal.pone.0152326 |
0.466 |
|
2016 |
Kondo K, Fujiki F, Nakajima H, Yatsukawa E, Morimoto S, Tatsumi N, Nishida S, Nakata J, Oka Y, Tsuboi A, Hosen N, Oji Y, Sugiyama H. An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). 39: 127-39. PMID 26938946 DOI: 10.1097/CJI.0000000000000114 |
0.379 |
|
2016 |
Hosen N, Hasegawa K, Aoyama Y, Ichihara H, Mugitani A, Nakao T, Manabe M, Oji Y, Sugiyama H. Identification of New Multiple Myeloma-Specific Cell Surface Antigens As Immunotherapeutic Targets Blood. 128: 3252-3252. DOI: 10.1182/blood.V128.22.3252.3252 |
0.316 |
|
2016 |
Kondo K, Fujiki F, Nakajima H, Yatsukawa E, Morimoto S, Tatsumi N, Nishida S, Nakata J, Oka Y, Tsuboi A, Hosen N, Oji Y, Sugiyama H. An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells Journal of Immunotherapy. DOI: 10.1097/CJI.0000000000000114 |
0.357 |
|
2015 |
Hasegawa K, Tanaka S, Fujiki F, Morimoto S, Nakajima H, Tatsumi N, Nakata J, Takashima S, Nishida S, Tsuboi A, Oka Y, Oji Y, Kumanogoh A, Sugiyama H, Hosen N. An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells. Plos One. 10: e0144594. PMID 26658107 DOI: 10.1371/journal.pone.0144594 |
0.436 |
|
2015 |
Hosen N. [Identification and targeting of multiple myeloma stem cells]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 73: 816-22. PMID 25985637 |
0.322 |
|
2015 |
Katsuhara A, Fujiki F, Aoyama N, Tanii S, Morimoto S, Oka Y, Tsuboi A, Nakajima H, Kondo K, Tatsumi N, Nakata J, Nakae Y, Takashima S, Nishida S, Hosen N, et al. Transduction of a novel HLA-DRB1*04:05-restricted, WT1-specific TCR gene into human CD4+ T cells confers killing activity against human leukemia cells. Anticancer Research. 35: 1251-61. PMID 25750272 |
0.346 |
|
2015 |
Hosen N. [Multiple myeloma stem cell]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 73: 47-51. PMID 25626303 |
0.47 |
|
2014 |
Kijima N, Hosen N, Kagawa N, Hashimoto N, Kinoshita M, Oji Y, Sugiyama H, Yoshimine T. Wilms' tumor 1 is involved in tumorigenicity of glioblastoma by regulating cell proliferation and apoptosis. Anticancer Research. 34: 61-7. PMID 24403445 |
0.39 |
|
2014 |
Nakata J, Nakano K, Okumura A, Mizutani Y, Kinoshita H, Iwai M, Hasegawa K, Morimoto S, Fujiki F, Tatsumi N, Nakajima H, Nakae Y, Nishida S, Tsuboi A, Oji Y, ... ... Hosen N, et al. In vivo eradication of MLL/ENL leukemia cells by NK cells in the absence of adaptive immunity. Leukemia. 28: 1316-25. PMID 24336127 DOI: 10.1038/leu.2013.374 |
0.427 |
|
2013 |
Lin Y, Fujiki F, Katsuhara A, Oka Y, Tsuboi A, Aoyama N, Tanii S, Nakajima H, Tatsumi N, Morimoto S, Tamanaka T, Tachino S, Hosen N, Nishida S, Oji Y, et al. HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). 36: 159-70. PMID 23502763 DOI: 10.1097/CJI.0b013e3182873581 |
0.392 |
|
2013 |
Hosen N. Multiple myeloma-initiating cells. International Journal of Hematology. 97: 306-12. PMID 23420183 DOI: 10.1007/s12185-013-1293-0 |
0.47 |
|
2012 |
Hosen N, Matsuoka Y, Kishida S, Nakata J, Mizutani Y, Hasegawa K, Mugitani A, Ichihara H, Aoyama Y, Nishida S, Tsuboi A, Fujiki F, Tatsumi N, Nakajima H, Hino M, et al. CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients. Leukemia. 26: 2135-41. PMID 22430638 DOI: 10.1038/leu.2012.80 |
0.391 |
|
2012 |
Kijima N, Hosen N, Kagawa N, Hashimoto N, Nakano A, Fujimoto Y, Kinoshita M, Sugiyama H, Yoshimine T. CD166/activated leukocyte cell adhesion molecule is expressed on glioblastoma progenitor cells and involved in the regulation of tumor cell invasion. Neuro-Oncology. 14: 1254-64. PMID 22166264 DOI: 10.1093/neuonc/nor202 |
0.469 |
|
2012 |
Morimoto S, Oka Y, Tsuboi A, Tanaka Y, Fujiki F, Nakajima H, Hosen N, Nishida S, Nakata J, Nakae Y, Maruno M, Myoui A, Enomoto T, Izumoto S, Sekimoto M, et al. Biased usage of T cell receptor β-chain variable region genes of Wilms' tumor gene (WT1)-specific CD8+ T cells in patients with solid tumors and healthy donors. Cancer Science. 103: 408-14. PMID 22126448 DOI: 10.1111/j.1349-7006.2011.02163.x |
0.32 |
|
2012 |
Hosen N, Ichihara H, Mugitani A, Aoyama Y, Fukuda Y, Kishida S, Matsuoka Y, Nakajima H, Kawakami M, Yamagami T, Fuji S, Tamaki H, Nakao T, Nishida S, Tsuboi A, et al. CD48 as a novel molecular target for antibody therapy in multiple myeloma. British Journal of Haematology. 156: 213-24. PMID 22098460 DOI: 10.1111/j.1365-2141.2011.08941.x |
0.331 |
|
2010 |
Murao A, Oka Y, Tsuboi A, Elisseeva OA, Tanaka-Harada Y, Fujiki F, Nakajima H, Nishida S, Hosen N, Shirakata T, Hashimoto N, Myoui A, Ueda T, Takeda Y, Osaki T, et al. High frequencies of less differentiated and more proliferative WT1-specific CD8+ T cells in bone marrow in tumor-bearing patients: an important role of bone marrow as a secondary lymphoid organ. Cancer Science. 101: 848-54. PMID 20136847 DOI: 10.1111/j.1349-7006.2009.01468.x |
0.401 |
|
2010 |
Tanaka-Harada Y, Kawakami M, Oka Y, Tsuboi A, Katagiri T, Elisseeva OA, Nishida S, Shirakata T, Hosen N, Fujiki F, Murao A, Nakajima H, Oji Y, Kanda Y, Kawase I, et al. Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies. Cancer Science. 101: 594-600. PMID 20132220 DOI: 10.1111/j.1349-7006.2009.01453.x |
0.353 |
|
2010 |
Martínez-Estrada OM, Lettice LA, Essafi A, Guadix JA, Slight J, Velecela V, Hall E, Reichmann J, Devenney PS, Hohenstein P, Hosen N, Hill RE, Muñoz-Chapuli R, Hastie ND. Wt1 is required for cardiovascular progenitor cell formation through transcriptional control of Snail and E-cadherin. Nature Genetics. 42: 89-93. PMID 20023660 DOI: 10.1038/ng.494 |
0.454 |
|
2010 |
Hosen N, Sugiyama H. Clonogenic MM Progenitor Cells Reside In CD19-CD38++ Plasma Cells Blood. 116: 1897-1897. DOI: 10.1182/blood.v116.21.1897.1897 |
0.362 |
|
2009 |
Papathanasiou P, Attema JL, Karsunky H, Hosen N, Sontani Y, Hoyne GF, Tunningley R, Smale ST, Weissman IL. Self-renewal of the long-term reconstituting subset of hematopoietic stem cells is regulated by Ikaros. Stem Cells (Dayton, Ohio). 27: 3082-92. PMID 19816952 DOI: 10.1002/Stem.232 |
0.572 |
|
2009 |
Yamane T, Hosen N, Yamazaki H, Weissman IL. Expression of AA4.1 marks lymphohematopoietic progenitors in early mouse development. Proceedings of the National Academy of Sciences of the United States of America. 106: 8953-8. PMID 19458045 DOI: 10.1073/pnas.0904090106 |
0.594 |
|
2009 |
Martínez-Estrada OM, Lettice LA, Essafi A, Guadix JA, Slight J, Hall E, Velecela V, Reichmann J, Devenney PS, Hohenstein P, Hosen N, Hill RE, Muñoz-Chapuli R, Hastie ND. 03-P107 EMT regulated by Wt1 through transcriptional control of Snail-1 and E-cadherin is required for generation of progenitor cells in epicardium and ES cells Mechanisms of Development. 126: S98-S99. DOI: 10.1016/j.mod.2009.06.160 |
0.358 |
|
2007 |
Tsuboi A, Oka Y, Nakajima H, Fukuda Y, Elisseeva OA, Yoshihara S, Hosen N, Ogata A, Kito K, Fujiki F, Nishida S, Shirakata T, Ohno S, Yasukawa M, Oji Y, et al. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. International Journal of Hematology. 86: 414-7. PMID 18192109 DOI: 10.1532/IJH97.07007 |
0.337 |
|
2007 |
Bhattacharya D, Cheah MT, Franco CB, Hosen N, Pin CL, Sha WC, Weissman IL. Transcriptional profiling of antigen-dependent murine B cell differentiation and memory formation. Journal of Immunology (Baltimore, Md. : 1950). 179: 6808-19. PMID 17982071 DOI: 10.4049/Jimmunol.179.10.6808 |
0.392 |
|
2007 |
Hosen N, Park CY, Tatsumi N, Oji Y, Sugiyama H, Gramatzki M, Krensky AM, Weissman IL. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia Proceedings of the National Academy of Sciences of the United States of America. 104: 11008-11013. PMID 17576927 DOI: 10.1073/Pnas.0704271104 |
0.637 |
|
2007 |
Hosen N, Shirakata T, Nishida S, Yanagihara M, Tsuboi A, Kawakami M, Oji Y, Oka Y, Okabe M, Tan B, Sugiyama H, Weissman IL. The Wilms' tumor gene WT1-GFP knock-in mouse reveals the dynamic regulation of WT1 expression in normal and leukemic hematopoiesis Leukemia. 21: 1783-1791. PMID 17525726 DOI: 10.1038/sj.leu.2404752 |
0.57 |
|
2007 |
Hosen N, Yamane T, Muijtjens M, Pham K, Clarke MF, Weissman IL. Bmi-1-green fluorescent protein-knock-in mice reveal the dynamic regulation of bmi-1 expression in normal and leukemic hematopoietic cells. Stem Cells (Dayton, Ohio). 25: 1635-44. PMID 17395774 DOI: 10.1182/Blood.V108.11.1338.1338 |
0.674 |
|
2006 |
Jomgeow T, Oji Y, Tsuji N, Ikeda Y, Ito K, Tsuda A, Nakazawa T, Tatsumi N, Sakaguchi N, Takashima S, Shirakata T, Nishida S, Hosen N, Kawakami M, Tsuboi A, et al. Wilms' tumor gene WT1 17AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro. Cancer Science. 97: 259-70. PMID 16630117 DOI: 10.1111/j.1349-7006.2006.00169.x |
0.391 |
|
2006 |
Nishida S, Hosen N, Shirakata T, Kanato K, Yanagihara M, Nakatsuka S, Hoshida Y, Nakazawa T, Harada Y, Tatsumi N, Tsuboi A, Kawakami M, Oka Y, Oji Y, Aozasa K, et al. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. Blood. 107: 3303-12. PMID 16380455 DOI: 10.1182/blood-2005-04-1656 |
0.351 |
|
2006 |
Hosen N, Passegue E, Weissman IL. AML1/ETO and PML/RAR α Can Immortalize Committed Myeloid Progenitor Cells In-Vitro but Not Expand Them In-Vivo. Blood. 108: 2544-2544. DOI: 10.1182/Blood.V108.11.2544.2544 |
0.679 |
|
2006 |
Hosen N, Sugiyama H, Weissman IL. The Wilms’ Tumor Gene WT1 Is Over-Expressed in Immature Leukemia Cells but Not Necessary for Leukemia Development in Mouse Leukemia Models. Blood. 108: 1429-1429. DOI: 10.1182/Blood.V108.11.1429.1429 |
0.631 |
|
2005 |
Kanato K, Hosen N, Yanagihara M, Nakagata N, Shirakata T, Nakazawa T, Nishida S, Tsuboi A, Kawakami M, Masuda T, Oka Y, Oji Y, Ijpenberg A, Hastie ND, Sugiyama H. The Wilms' tumor gene WT1 is a common marker of progenitor cells in fetal liver. Biochemical and Biophysical Research Communications. 326: 836-43. PMID 15607745 DOI: 10.1016/j.bbrc.2004.11.107 |
0.368 |
|
2004 |
Kawakami M, Kimura T, Kishimoto Y, Tatekawa T, Baba Y, Nishizaki T, Matsuzaki N, Taniguchi Y, Yoshihara S, Ikegame K, Shirakata T, Nishida S, Masuda T, Hosen N, Tsuboi A, et al. Preferential expression of the vasoactive intestinal peptide (VIP) receptor VPAC1 in human cord blood-derived CD34+CD38- cells: possible role of VIP as a growth-promoting factor for hematopoietic stem/progenitor cells. Leukemia. 18: 912-21. PMID 14999295 DOI: 10.1038/sj.leu.2403330 |
0.393 |
|
2004 |
Hosen N, Yanagihara M, Nakazawa T, Kanato K, Nishida S, Shirakata T, Asada M, Masuda T, Taniguchi Y, Kawakami M, Tsuboi A, Ikegame K, Oka Y, Ogawa H, Kawase I, et al. Identification of a gene element essential for leukemia-specific expression of transgenes. Leukemia. 18: 415-9. PMID 14737070 DOI: 10.1038/sj.leu.2403260 |
0.351 |
|
2003 |
Fujioka T, Taniguchi Y, Masuda T, Nishida S, Ikegame K, Kawakami M, Tsuboi A, Hosen N, Murakami M, Oji Y, Oka Y, Sugiyama H, Kawase I, Ogawa H. The effect on the proliferation and apoptosis of alloreactive T cells of cell dose in a murine MHC-mismatched hematopoietic cell transplantation model. Transplant Immunology. 11: 187-95. PMID 12799203 DOI: 10.1016/S0966-3274(03)00005-4 |
0.385 |
|
2002 |
Hosen N, Sonoda Y, Oji Y, Kimura T, Minamiguchi H, Tamaki H, Kawakami M, Asada M, Kanato K, Motomura M, Murakami M, Fujioka T, Masuda T, Kim EH, Tsuboi A, et al. Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells. British Journal of Haematology. 116: 409-20. PMID 11841446 DOI: 10.1046/j.1365-2141.2002.03261.x |
0.414 |
|
Show low-probability matches. |